INTELLIGENT
VIRUS DEFENSE
Introducing Centinel™ Intelligent Virus Defense, the first commercially
available gene-editing tool to confer viral resistance to CHO cell lines.
At MilliporeSigma, we’re committed to developing leading-edge
solutions to advance the biopharma manufacturing industry.
With Centinel™, you leverage a powerful combination of tailored
biologic solutions and advanced gene-editing technologies to ensure
manufacturing processes that are both secure and sustainable.
VIRAL RESISTANCE FOR THE FUTURE.
Centinel™ technology goes beyond viral insurance. It’s
an integral component of a sophisticated virus mitigation
strategy for preventing, detecting and removing viruses.
• Drive organizational value by reducing
the risk of viral contamination
• Defend valuable product investment
from potential harm
• Deliver advanced virus resistance to
biopharmaceutical manufacturers, supporting
process efficiency and consumer safety
CENTINEL™ STEP-BY-STEP
• GENE-EDITING REAGENTS FOR ENGINEERING
A VIRAL-RESISTANT CELL LINE
• CELL-LINE ENGINEERING SERVICES FOR
VIRAL RESISTANCE
• VIRAL CHALLENGE ASSAYS BY BIORELIANCE®
FOR CONFIRMING VIRAL RESISTANCE
EMD Millipore Corporation
290 Concord Road
Billerica, MA 01821
+1 (800) 645-5476
Pharma/Biopharma Raw Materials
DEFEND TRUE
BIOADVANCEMENT
MilliporeSigma has identified a gene target (Slc35A1) that, upon
elimination of expression by gene editing, results in a CHO cell line
that is resistant to infection by Minute Virus of Mice (MVM). You’ll call
it progress. We call it bioadvancement.
An 8-day, side-by-side study was conducted to assess resistance in
Slc35A1 knockout cells. Both wildtype and Slc35A1 knockout cells were
exposed to MVM.
• Immediate loss of viability and lack of propagation was observed in
exposed wildtype cells
• Growth was not affected by MVM exposure in the Slc35A1 knockout cells,
indicating the wildtype cells were susceptible to infection while the
Slc35A1 knockout cells were resistant
Growth of Wildtype CHO Cells With
and Without Exposure to MVM
Growth of Slc35A1 Knockout CHO Cells With
and Without Exposure to MVM
7
8
6
4
2
0
0
2
4
6
8
6
5
4
2.5x108
3
2
1
0
0
2
Days in Culture
WT CHO Uninfected
WT CHO Infected
4
6
8
Days in Culture
Slc35A1 Knockout CHO Uninfected
Slc35A1 Knockout CHO Infected
Wildtype and Slc35A1 knockout cells infected with MVM at an MOI of 1.0. Viable cell density determined through
Day 8, post infection.
Viral Genome Copies
per Samle
Viable Cell Density
(10^6 cells/ml)
Viable Cell Density
(10^6 cells/ml)
10
Wildtype and Slc35A1 knockout
cells were incubated with MVM
for 3 hours and then washed to
remove non-specifically bound
virus. Samples were then collected
at 0 hours and 21 hours and
analyzed by qPCR using a probe
against the MVM NS2 gene.
Time 0 indicates levels of viral
attachment. Time 21 indicates
levels of internalization and single
cycle replication. No replication
is observed in the Slc35A1
knockout cells.
2.0x108
1.5x108
1.0x108
5.0x107
12000
0
T=0
T=0
Wild Type
VISIT: WWW.SIAL.COM/CENTINEL
The life science business of Merck KGaA, Darmstadt, Germany
operates as MilliporeSigma in the U.S. and Canada.
MilliporeSigma, the vibrant M and Centinel are trademarks of Merck KGaA, Darmstadt, Germany. Sigma-Aldrich, BioReliance
and CHOZN are registered trademarks of Sigma-Aldrich Co. LLC. All trademarks are the property of their respective owners.
© 2016 EMD Millipore Corporation, Billerica, MA USA. All rights reserved.
T=21
T=21
Hours Post Infection
Slc35A1 Knockout
Wildtype and Slc35A1 knockout cells exposed to MVM.
MVM replication is abrogated in Slc35A1 knockout
cell line.